Skip to content

Advertisement

Basic Tumor Immunology

Section edited by Cornelis J.M. Melief, MD, PhD

Tumor antigens, innate and adaptive anti-tumor immune mechanisms, immune regulation, immune response, cancer and inflammation, preclinical models, chemotherapy and radiotherapy interactions/combinations of chemotherapy and radiotherapy, other combination treatments with the anti-tumor immune response, and oncolytic viruses.

  1. Content type: Research article

    Women diagnosed with breast cancer within 5 years postpartum (PPBC) have poorer prognosis than age matched nulliparous women, even after controlling for clinical variables known to impact disease outcomes. Thr...

    Authors: Nathan D. Pennock, Holly A. Martinson, Qiuchen Guo, Courtney B. Betts, Sonali Jindal, Takahiro Tsujikawa, Lisa M. Coussens, Virginia F. Borges and Pepper Schedin

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:98

    Published on:

  2. Content type: Commentary

    Immunotherapy is rapidly becoming the fourth arm of cancer treatment, and breakthrough successes have been observed in multiple malignancies. However, despite the potential for impressive anti-tumor effects, o...

    Authors: Robert J. Canter and William J. Murphy

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:79

    Published on:

  3. Content type: Research article

    Mutation-derived neoantigens represent an important class of tumour-specific, tumour rejection antigens, and are attractive targets for TCR gene therapy of cancer. The majority of such mutations are patient-sp...

    Authors: Vanessa M. Tubb, Deborah S. Schrikkema, Nathan P. Croft, Anthony W. Purcell, Carsten Linnemann, Manon R. Freriks, Frederick Chen, Heather M. Long, Steven P. Lee and Gavin M. Bendle

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:70

    Published on:

  4. Content type: Short report

    Antiviral responses are barriers that must be overcome for efficacy of oncolytic virotherapy. In mammalian cells, antiviral responses involve the interferon pathway, a protein-signaling cascade that alerts the...

    Authors: Donald Bastin, Amelia S. Aitken, Adrian Pelin, Larissa A. Pikor, Mathieu J. F. Crupi, Michael S. Huh, Marie-Claude Bourgeois-Daigneault, John C. Bell and Carolina S. Ilkow

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:62

    Published on:

  5. Content type: Research article

    The clinical efficacy observed with inhibitors of programed cell death 1/programed cell death ligand 1 (PD-L1/PD-1) in cancer therapy has prompted studies to characterize the immune response in several tumor t...

    Authors: Edwin R. Parra, Pamela Villalobos, Carmen Behrens, Mei Jiang, Apar Pataer, Stephen G. Swisher, William N. William Jr, Jiexin Zhang, Jack Lee, Tina Cascone, John V. Heymach, Marie-Andrée Forget, Cara Haymaker, Chantale Bernatchez, Neda Kalhor, Annikka Weissferdt…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:48

    Published on:

  6. Content type: Research article

    Receptors specific for the sugar N-acetylgalactosamine (GalNAc) include the human type II, C-type lectin receptor macrophage galactose-type lectin/C-type lectin receptor family member 10A (MGL/CLEC10A/CD301) that...

    Authors: Laura L. Eggink, Katherine F. Roby, Robert Cote and J. Kenneth Hoober

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:28

    Published on:

  7. Content type: Research article

    Numerous oncology combination therapies involving modulators of the cancer immune cycle are being developed, yet quantitative simulation models predictive of outcome are lacking. We here present a model-based ...

    Authors: Yuri Kosinsky, Simon J. Dovedi, Kirill Peskov, Veronika Voronova, Lulu Chu, Helen Tomkinson, Nidal Al-Huniti, Donald R. Stanski and Gabriel Helmlinger

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:17

    Published on:

  8. Content type: Research article

    Immuno-oncotherapy has emerged as a promising means to target cancer. In particular, therapeutic manipulation of tumor-associated macrophages holds promise due to their various and sometimes opposing roles in ...

    Authors: Grace Mahlbacher, Louis T. Curtis, John Lowengrub and Hermann B. Frieboes

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:10

    Published on:

  9. Content type: Research article

    Myeloid cells are an abundant leukocyte in many types of tumors and contribute to immune evasion. Expression of the enzyme arginase 1 (Arg1) is a defining feature of immunosuppressive myeloid cells and leads t...

    Authors: Susanne M. Steggerda, Mark K. Bennett, Jason Chen, Ethan Emberley, Tony Huang, Julie R. Janes, Weiqun Li, Andrew L. MacKinnon, Amani Makkouk, Gisele Marguier, Peter J. Murray, Silinda Neou, Alison Pan, Francesco Parlati, Mirna L. M. Rodriguez, Lee-Ann Van de Velde…

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:101

    Published on:

  10. Content type: Research article

    Colorectal cancer is responsible for almost 700,000 deaths annually worldwide. Therapeutic vaccination is a promising alternative to conventional treatment for colorectal cancer, using vaccines to induce targe...

    Authors: Braeden Donaldson, Farah Al-Barwani, Simon J. Pelham, Katie Young, Vernon K. Ward and Sarah L. Young

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:69

    Published on:

  11. Content type: Research article

    The suppressive nature of immune cells in the tumor microenvironment plays a major role in regulating anti-tumor immune responses. Our previous work demonstrated that a soluble factor from tumor cells is able ...

    Authors: Brian T. Maybruck, Lukas W. Pfannenstiel, Marcela Diaz-Montero and Brian R. Gastman

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:65

    Published on:

  12. Content type: Research article

    T-cell checkpoint blockade and MEK inhibitor combinations are under clinical investigation. Despite progress elucidating the immuno-modulatory effects of MEK inhibitors as standalone therapies, the impact of M...

    Authors: Edmund Poon, Stefanie Mullins, Amanda Watkins, Geoffrey S. Williams, Jens-Oliver Koopmann, Gianfranco Di Genova, Marie Cumberbatch, Margaret Veldman-Jones, Shaun E. Grosskurth, Vasu Sah, Alwin Schuller, Corrine Reimer, Simon J. Dovedi, Paul D. Smith, Ross Stewart and Robert W. Wilkinson

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:63

    Published on:

  13. Content type: Research article

    We previously demonstrated that in addition to generating an antigen-specific immune response, Listeria monocytogenes (Lm)-based immunotherapy significantly reduces the ratio of regulatory T cells (Tregs)/CD4+ an...

    Authors: Rajeev Shrimali, Shamim Ahmad, Zuzana Berrong, Grigori Okoev, Adelaida Matevosyan, Ghazaleh Shoja E. Razavi, Robert Petit, Seema Gupta, Mikayel Mkrtichyan and Samir N. Khleif

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:64

    Published on:

  14. Content type: Research article

    The expansion of antigen-specific CD8 T cells is important in generating an effective and long-lasting immune response to tumors and viruses. Glucocorticoid-induced tumor necrosis factor receptor family-relate...

    Authors: Nick M. Durham, Nick Holoweckyj, Randall S. MacGill, Kelly McGlinchey, Ching Ching Leow and Scott H. Robbins

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:47

    Published on:

  15. Content type: Research article

    Adoptive cellular therapy (ACT) with cancer antigen-reactive T cells following lymphodepletive pre-conditioning has emerged as a potentially curative therapy for patients with advanced cancers. However, identi...

    Authors: Weiqing Jing, Jill A. Gershan, Grace C. Blitzer, Katie Palen, James Weber, Laura McOlash, Matthew Riese and Bryon D. Johnson

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:51

    Published on:

  16. Content type: Research article

    Clinical success with chimeric antigen receptor (CAR)- based immunotherapy for leukemia has been accompanied by the associated finding that antigen-escape variants of the disease are responsible for relapse. T...

    Authors: Dina Schneider, Ying Xiong, Darong Wu, Volker Nӧlle, Sarah Schmitz, Waleed Haso, Andrew Kaiser, Boro Dropulic and Rimas J. Orentas

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:42

    Published on:

  17. Content type: Research article

    Human γδ T cells expressing Vγ2Vδ2 T cell receptors monitor foreign- and self-prenyl pyrophosphate metabolites in isoprenoid biosynthesis to mediate immunity to microbes and tumors. Adoptive immunotherapy with...

    Authors: Mohanad H. Nada, Hong Wang, Grefachew Workalemahu, Yoshimasa Tanaka and Craig T. Morita

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:9

    Published on:

  18. Content type: Research article

    Although therapeutic cancer vaccines have been mostly disappointing in the clinic, the advent of novel immunotherapies and the future promise of neoantigen-based therapies have created the need for new vaccine...

    Authors: James T. Gordy, Kun Luo, Hong Zhang, Arya Biragyn and Richard B. Markham

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:96

    Published on:

  19. Content type: Research article

    Tumors avoid destruction by cytotoxic T cells (CTL) and natural killer (NK) cells by downregulation of classical human leukocyte antigens (HLA) and overexpression of non-classical HLA. This is the first study ...

    Authors: Debbie M. Ferns, A. Marijne Heeren, Sanne Samuels, Maaike C. G. Bleeker, Tanja D. de Gruijl, Gemma G. Kenter and Ekaterina S. Jordanova

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:78

    Published on:

  20. Content type: Research article

    Future cancer immunotherapies will combine multiple treatments to generate functional immune responses to cancer antigens through synergistic, multi-modal mechanisms. In this study we explored the combination ...

    Authors: Genevieve M. Weir, Olga Hrytsenko, Tara Quinton, Neil L. Berinstein, Marianne M. Stanford and Marc Mansour

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:68

    Published on:

  21. Content type: Research article

    Ovarian cancer (OvCA) tissues show abundant expression of the ectonucleotidases CD39 and CD73 which generate immunomodulatory adenosine, thereby inhibiting cytotoxic lymphocytes. Little, however, is known abou...

    Authors: Itsaso Montalbán del Barrio, Cornelia Penski, Laura Schlahsa, Roland G. Stein, Joachim Diessner, Achim Wöckel, Johannes Dietl, Manfred B. Lutz, Michel Mittelbronn, Jörg Wischhusen and Sebastian F. M. Häusler

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:49

    Published on:

  22. Content type: Research article

    Therapeutic resistance and tumor recurrence are two major hurdles in the treatment of pancreatic ductal adenocarcinoma. Recent findings suggest that both of these attributes are associated with a small subset ...

    Authors: Jason W.-L. Eng, Thomas A. Mace, Rohit Sharma, Danielle Y. F. Twum, Peng Peng, John F. Gibbs, Rosemarie Pitoniak, Chelsey B. Reed, Scott I. Abrams, Elizabeth A. Repasky and Bonnie L. Hylander

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:33

    Published on:

  23. Content type: Research article

    Adoptive T-cell based immunotherapies constitute a promising approach to treat cancer, however, a major problem is to obtain effective and long-lasting anti-tumor responses. Lack of response may be due to insu...

    Authors: Imran Siddiqui, Marco Erreni, Mandy van Brakel, Reno Debets and Paola Allavena

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:21

    Published on:

  24. Content type: Research article

    Lymphodepletion enhances adoptive T cell transfer (ACT) therapy by activating the innate immune system via microbes released from the radiation-injured gut. Microbial components, such as LPS, are key mediators...

    Authors: Michelle H. Nelson, Jacob S. Bowers, Stefanie R. Bailey, Marshall A. Diven, Caroline W. Fugle, Andrew D. M. Kaiser, Claudia Wrzesinski, Bei Liu, Nicholas P. Restifo and Chrystal M. Paulos

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:6

    Published on:

  25. Content type: Research article

    A current focus in cancer treatment is to broaden responses to immunotherapy. One reason these therapies may prove inadequate is that T lymphocytes fail to recognize the tumor due to differences in immunogenic...

    Authors: Katherine Woods, Ashley J. Knights, Matthew Anaka, Ralf B. Schittenhelm, Anthony W. Purcell, Andreas Behren and Jonathan Cebon

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:10

    Published on:

  26. Content type: Research article

    Annexin A2 (ANXA2) is a pleiotropic, calcium-dependent, phospholipid-binding protein with a broad tissue distribution. It can be intracellular, membrane-bound, or secreted, and it exists as a monomer or hetero...

    Authors: Brian M. Andersen, Junzhe Xia, Alan L. Epstein, John R. Ohlfest, Wei Chen, Bruce R. Blazar, Christopher A. Pennell and Michael R. Olin

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:11

    Published on:

  27. Content type: Research article

    Tasquinimod (a quinoline-3-carboxyamide) is a small molecule immunotherapy with demonstrated effects on the tumor microenvironment (TME) involving immunomodulation, anti-angiogenesis and inhibition of metastas...

    Authors: Anders Olsson, Jessica Nakhlé, Anette Sundstedt, Pascale Plas, Anne-Laure Bauchet, Valérie Pierron, Luce Bruetschy, Adnan Deronic, Marie Törngren, David Liberg, Fabien Schmidlin and Tomas Leanderson

    Citation: Journal for ImmunoTherapy of Cancer 2015 3:53

    Published on:

  28. Content type: Research article

    Adoptive cell transfer of tumor-specific T lymphocytes (T cells) is proving to be an effective strategy for treating established tumors in cancer patients. One method of generating these cells is accomplished ...

    Authors: Joanne A. Hammill, Heather VanSeggelen, Christopher W. Helsen, Galina F. Denisova, Carole Evelegh, Daniela G. M. Tantalo, Jennifer D. Bassett and Jonathan L. Bramson

    Citation: Journal for ImmunoTherapy of Cancer 2015 3:55

    Published on:

  29. Content type: Research article

    Clinical targeting of TNFR family of receptors (CD40, CD134 and CD137) with immunostimulatory monoclonal antibodies has been successful in cancer immunotherapy. However, targeting of CD27 with a mAb is a relat...

    Authors: Venky Ramakrishna, Karuna Sundarapandiyan, Biwei Zhao, Max Bylesjo, Henry C. Marsh and Tibor Keler

    Citation: Journal for ImmunoTherapy of Cancer 2015 3:37

    Published on:

  30. Content type: Research article

    Melanoma is one of the few types of cancer with an increasing annual incidence. While a number of immunotherapies for melanoma have been associated with significant clinical benefit, including high-dose IL-2 a...

    Authors: Frederick J Kohlhapp, Joseph R Broucek, Tasha Hughes, Erica J Huelsmann, Jevgenijs Lusciks, Janet P Zayas, Hubert Dolubizno, Vidyaratna A Fleetwood, Alisa Grin, Graham E Hill, Joseph L Poshepny, Arman Nabatiyan, Carl E Ruby, Joshua D Snook, Jai S Rudra, Jason M Schenkel…

    Citation: Journal for ImmunoTherapy of Cancer 2015 3:18

    Published on:

  31. Content type: Research article

    Ovarian cancer is immunogenic and residual tumor volume after surgery is known to be prognostic. Ovarian cancer often follows a recurring-remitting course and microscopic disease states may present ideal oppor...

    Authors: John B Liao, Kelsie J Ovenell, Erin E M Curtis, Denise L Cecil, Marlese R Koehnlein, Lauren R Rastetter, Ekram A Gad and Mary L Disis

    Citation: Journal for ImmunoTherapy of Cancer 2015 3:16

    Published on:

  32. Content type: Research article

    The complex interactions that occur between human tumors, tumor infiltrating lymphocytes (TIL) and the systemic immune system are likely to define critical factors in the host response to cancer. While convent...

    Authors: Michael D Roth and Airi Harui

    Citation: Journal for ImmunoTherapy of Cancer 2015 3:12

    Published on:

  33. Content type: Research article

    Multiple myeloma is characterized by the presence of transformed neoplastic plasma cells in the bone marrow and is generally considered to be an incurable disease. Successful treatments will likely require mul...

    Authors: Weiqing Jing, Jill A Gershan, James Weber, Dominique Tlomak, Laura McOlash, Catherine Sabatos-Peyton and Bryon D Johnson

    Citation: Journal for ImmunoTherapy of Cancer 2015 3:2

    Published on:

  34. Content type: Research article

    T cells have the capacity to eliminate tumors but the signaling pathways by which they do so are incompletely understood. T cell priming requires activation of the transcription factors AP-1, NFAT and NF-κB do...

    Authors: Sarah E Barnes, Ying Wang, Luqiu Chen, Luciana L Molinero, Thomas F Gajewski, Cesar Evaristo and Maria-Luisa Alegre

    Citation: Journal for ImmunoTherapy of Cancer 2015 3:1

    Published on:

  35. Content type: Research article

    Therapeutic cancer vaccines aim to boost the natural immunity against transformed cancer cells, and a series of adjuvants and co-stimulatory molecules have been proposed to enhance the immune response against ...

    Authors: Stéphanie Corgnac, Rachel Perret, Lianjun Zhang, Jean-Pierre Mach, Pedro Romero and Alena Donda

    Citation: Journal for ImmunoTherapy of Cancer 2014 2:39

    Published on:

  36. Content type: Research article

    Invariant natural killer T (iNKT) cells are CD1d-restricted T cells, which respond rapidly to antigen recognition and promote development of anti-tumor immunity in many tumor models. Surprisingly, we previousl...

    Authors: Karsten A Pilones, Joseph Aryankalayil, James S Babb and Sandra Demaria

    Citation: Journal for ImmunoTherapy of Cancer 2014 2:37

    Published on:

  37. Content type: Research article

    Several members of the common gamma chain (gc) cytokine family are already approved (IL-2) or actively being developed as vaccine adjuvants and cancer immunotherapies. Studies have indicated that co-administra...

    Authors: Michael J McNamara, Melissa J Kasiewicz, Stefanie N Linch, Christopher Dubay and William L Redmond

    Citation: Journal for ImmunoTherapy of Cancer 2014 2:28

    Published on:

  38. Content type: Research article

    The development of immunotherapy has led to significant progress in the treatment of metastatic cancer, including the development of genetic engineering technologies that redirect lymphocytes to recognize and ...

    Authors: Rachel E Beard, Zhili Zheng, Kiran H Lagisetty, William R Burns, Eric Tran, Stephen M Hewitt, Daniel Abate-Daga, Shannon F Rosati, Howard A Fine, Soldano Ferrone, Steven A Rosenberg and Richard A Morgan

    Citation: Journal for ImmunoTherapy of Cancer 2014 2:25

    Published on:

  39. Content type: Research article

    Indoleamine 2,3-dioxygenase (IDO) is an enzyme with immune-suppressive properties that is commonly exploited by tumors to evade immune destruction. Anti-tumor T cell responses can be initiated in solid tumors,...

    Authors: Minghui Li, Aaron R Bolduc, Md Nasrul Hoda, Denise N Gamble, Sarah-Bianca Dolisca, Anna K Bolduc, Kelly Hoang, Claire Ashley, David McCall, Amyn M Rojiani, Bernard L Maria, Olivier Rixe, Tobey J MacDonald, Peter S Heeger, Andrew L Mellor, David H Munn…

    Citation: Journal for ImmunoTherapy of Cancer 2014 2:21

    Published on:

  40. Content type: Research article

    The TLR7/8 agonist 3M-052 and the TLR9 agonist CpG ODN both trigger innate immune responses that support the induction of tumor-specific immunity. Previous studies showed that these agonists used individually ...

    Authors: By Gan Zhao, John P Vasilakos, Debra Tross, Dmitri Smirnov and Dennis M Klinman

    Citation: Journal for ImmunoTherapy of Cancer 2014 2:12

    Published on:

  41. Content type: Research article

    Histone deacetylase (HDAC) inhibitors are a class of agents that have potent antitumor activity with a reported ability to upregulate MHC and costimulatory molecule expression. We hypothesized that epigenetic ...

    Authors: Dominique N Lisiero, Horacio Soto, Richard G Everson, Linda M Liau and Robert M Prins

    Citation: Journal for ImmunoTherapy of Cancer 2014 2:8

    Published on:

  42. Content type: Research article

    Myeloid-derived suppressor cells (MDSCs) are among the major obstacles that adjuvants for cancer vaccines have to overcome. These cells cross-present tumor-associated antigens (TAA) to naive T lymphocytes with...

    Authors: Audry Fernández, Liliana Oliver, Rydell Alvarez, Arletty Hernández, Judith Raymond, Luis E Fernández and Circe Mesa

    Citation: Journal for ImmunoTherapy of Cancer 2014 2:5

    Published on:

  43. Content type: Research article

    Blockade of immune inhibitory pathways is emerging as an important therapeutic modality for the treatment of cancer. Single agent treatments have partial anti-tumor activity in preclinical models and in human ...

    Authors: Stefani Spranger, Holly K Koblish, Brendan Horton, Peggy A Scherle, Robert Newton and Thomas F Gajewski

    Citation: Journal for ImmunoTherapy of Cancer 2014 2:3

    Published on:

  44. Content type: Research article

    Sub-lethal doses of radiation can alter the phenotype of target tissue by modulating gene expression and making tumor cells more susceptible to T-cell-mediated immune attack. We have previously shown that sub-...

    Authors: Anita Kumari, Ercan Cacan, Susanna F Greer and Charlie Garnett-Benson

    Citation: Journal for ImmunoTherapy of Cancer 2013 1:17

    Published on:

  45. Content type: Research article

    One of the significant tumor immune escape mechanisms and substantial barrier for successful immunotherapy is tumor-mediated inhibition of immune response through cell-to-cell or receptor/ligand interactions. ...

    Authors: Mikayel Mkrtichyan, Namju Chong, Rasha Abu Eid, Anu Wallecha, Reshma Singh, John Rothman and Samir N Khleif

    Citation: Journal for ImmunoTherapy of Cancer 2013 1:15

    Published on:

  46. Content type: Research article

    Molecular imaging with positron emission tomography (PET) may allow the non-invasive study of the pharmacodynamic effects of agonistic monoclonal antibodies (mAb) to 4-1BB (CD137). 4-1BB is a member of the tum...

    Authors: Helena Escuin-Ordinas, Mark W Elliott, Mohammad Atefi, Michelle Lee, Charles Ng, Liu Wei, Begoña Comin-Anduix, Encarnacion Montecino-Rodriguez, Earl Avramis, Caius Radu, Leslie L Sharp and Antoni Ribas

    Citation: Journal for ImmunoTherapy of Cancer 2013 1:14

    Published on:

  47. Content type: Short report

    Treatment with agonist anti-CD137 (4-1BB) immunostimulatory monoclonal antibodies elicits complete tumor regressions in a number of transplanted hematological and solid malignancies in mice. Rejection is mainl...

    Authors: Aizea Morales-Kastresana, Elena Catalán, Sandra Hervás-Stubbs, Asis Palazón, Arantza Azpilikueta, Elixabet Bolaños, Alberto Anel, Julián Pardo and Ignacio Melero

    Citation: Journal for ImmunoTherapy of Cancer 2013 1:3

    Published on:

2017 Journal Metrics

Advertisement